Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Late doxorubicin cardiotoxicity.

M Lishner1, A Elis, M Ravid

  • 1Department of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Kfar Saba, Israel.

Anti-Cancer Drugs
|August 1, 1992
PubMed
Summary

Late-onset congestive heart failure (CHF) is rare in adults after doxorubicin treatment. This case highlights a 58-year-old woman with stage IV CHF 7 years post-treatment, emphasizing the importance of monitoring cardiac function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel agents for the treatment of lymphomas during pregnancy: A comprehensive literature review.

Blood reviews·2021
Same author

The characteristics of patients with possible familial hypercholesterolemia: screening a large payer/provider healthcare delivery system.

QJM : monthly journal of the Association of Physicians·2020
Same author

The characteristics of patients with possible familial hypercholesterolemia-screening a large payer/provider healthcare delivery system.

QJM : monthly journal of the Association of Physicians·2019
Same author

Epidemiology of cutaneous porphyria in Israel: a nationwide cohort study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

Challenges raised by the increased uptake of new anticoagulants.

QJM : monthly journal of the Association of Physicians·2018
Same author

Anticoagulation therapy in patients with non-valvular atrial fibrillation hospitalized in the Department of Medicine in the NOACs era.

QJM : monthly journal of the Association of Physicians·2018

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Doxorubicin is a common chemotherapy agent.
  • Cardiac toxicity is a known side effect of doxorubicin.
  • Late-onset congestive heart failure (CHF) is unusual as the initial presentation of doxorubicin-induced cardiac toxicity, particularly in adults.

Observation:

  • A 58-year-old woman presented with stage IV CHF 7 years after completing doxorubicin treatment for ovarian carcinoma.
  • Subclinical cardiac dysfunction was detected via radionuclide angiography 6 years before clinical CHF symptoms emerged.
  • This represents a rare and unique clinical course of doxorubicin-induced cardiac toxicity.

Findings:

  • The study details a rare case of late-onset, severe congestive heart failure (CHF) as the first clinical sign of doxorubicin-induced cardiac toxicity in an adult.
  • Subclinical cardiac dysfunction preceded overt CHF by six years, detected through radionuclide angiography.
  • The patient's unique disease progression and CHF management are discussed.

Implications:

  • This case underscores the potential for delayed and severe cardiac complications following doxorubicin therapy, even in adults.
  • Routine cardiac monitoring may be crucial for early detection of subclinical dysfunction in patients treated with doxorubicin.
  • Understanding these late-onset toxicities is vital for improving long-term survivorship and quality of life for cancer patients.

Related Experiment Videos